The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to PathoVax, LLC located in Baltimore, MD.
Document
Prospective Grant of Exclusive Patent License: Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent lice...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 23012
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent License: Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines,” thefederalregister.org (May 19, 2017), https://thefederalregister.org/documents/2017-10153/prospective-grant-of-exclusive-patent-license-chimeric-l1-l2-protein-and-virus-like-particles-based-human-papillomavirus.